INTRODUZIONE

Si riporta di seguito la produzione scientifica di Sifact aggiornata al 5 Novembre 2018 (solo le riviste censite da PubMed).

Anno 2018

  1. Badiani B, Chiumente M, Messori A. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs. Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:84-88. doi: 10.1016/j.ejogrb.2018.01.020.
  2. Damuzzo V, Russi A, Chiumente M, Masini C, Rebesco B, Gregis F, Nozza S,Pigozzo J, Chiarion-Sileni V, Palozzo AC. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. J Oncol Pharm Pract. 2018 Jan 1:1078155218755867. doi:10.1177/1078155218755867.
  3. Busa G, Burlina A, Damuzzo V, Chiumente M, Palozzo AC. Comorbidity, Polytherapy, and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs. J Pharm Pract. 2018 Feb;31(1):58-65. doi: 10.1177/0897190017699138.
  4. Mengato D., Messori A. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. Clin Exp Rheumatol. 2018 Mar 20.
  5. Chiumente MDamuzzo VAgnoletto LLeonardi LMengato D.  Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumab. Int J Clin Pharmacol Ther. 2018 Oct 26. doi: 10.5414/CP203348.

Anno 2017

  1. Chiumente M, Messori A. Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. Ther Adv Musculoskelet Dis. 2017 Oct;9(10):271-273. doi:10.1177/1759720X17721151.
  2. Chiumente M, Mengato D, Messori A. Rituximab biosimilar evaluated by network meta-analysis. Haematologica. 2017 Dec;102(12):e497-e498. doi:10.3324/haematol.2017.175042.
  3. Chiumente M, De Rosa M, Messori A, Proli EM. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women. Clinicoecon Outcomes Res. 2017 Aug 29;9:525-535. doi:10.2147/CEOR.S139335.
  4. Trippoli S, Chiumente M, Messori A. Promoting the use of Markovian simulation  models to study outcomes of thrombectomy after acute ischemic stroke. J Cardiovasc Med (Hagerstown). 2017 Oct;18(10):777-779. doi:10.2459/JCM.0000000000000532.
  5. Russi A, Damuzzo V, Chiumente M, Pigozzo J, Cesca M, Chiarion-Sileni V, Palozzo AC. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. J Chemother. 2017 Aug;29(4):245-251. doi:10.1080/1120009X.2017.1311444.
  6. Gutiérrez-Ibarluzea I, Chiumente M, Dauben HP. The Life Cycle of Health Technologies. Challenges and Ways Forward. Front Pharmacol. 2017 Jan 24;8:14. doi: 10.3389/fphar.2017.00014.

Anno 2016 

  1. Mengato D, Messori A. Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries. Ther Adv Med Oncol. 2016;Jul;8(4):309-11. doi: 10.1177/1758834016644465. Epub 2016 May 16.
  2. Palozzo AC, Messori A. Interventions of pharmaceutical disinvestment in the Italian national health system. Pharmacoeconomics  2016;34:419-420.
  3. Russi A, Serena M, Palozzo AC. Il prezzo dei farmaci oncologici va correlato al costo di sviluppo e produzione o al valore economico dell’efficacia clinica? Recenti Prog Med 2016; 107: 1-5  http://www.osservatorioinnovazione.net/papers/russi_rpm2016.pdf 
  4. Mueller D, Gutiérrez-Ibarluzea I, Schuller T, Chiumente M, Ahn J, Pichon-Riviere A, García-Martí S, Grainger D, Cobbs E, Marchetti M. CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT. Int J Technol Assess Health Care. 2016 Jan;32(4):292-299.
  5. Trippoli S, Chiumente M, Messori A. Differences in effectiveness among devices for endovascular thrombectomy in patients with acute ischemic stroke. J Stroke 2016;18(2):230-2.

Anno 2015

  1. Messori A, De Rosa M, Fadda V, Pani L. Effectiveness and cost effectiveness of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3838-9. http://www.osservatorioinnovazione.net/papers/jco2015.pdf
  2. Messori A, De Rosa M, Pani L. Alternative pricing strategies for cancer drugs. JAMA. 2015;313(8):857.  http://www.osservatorioinnovazione.net/papers/jama2015.pdf
  3. De Rosa M, Messori A. The safety of bevacizumab vs ranibizumab in non-randomized studies. Int Ophthalmol 2015;35(2):157-8.http://www.osservatorioinnovazione.net/papers/intjophthalmol2015.pdf

Progetti in corso


Aggiungi commento


Codice di sicurezza
Aggiorna